Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an "autopilot" rather than a "digital copilot" risks a dangerous "deskilling" ...

Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, education, screening, and diagnosis to drive earlier keratoconus detection. Epioxa ...

Physiologic AL varies materially with age, sex, height, and ethnicity, undermining fixed AL thresholds as broadly applicable risk stratifiers in typical pediatric myopia. Retinal pathology risk ...

NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset activity within minutes versus existing therapies requiring weeks to months.